Fund name changeConfirmed 8 September 2025
SEB Concept Biotechnology to merge into SEB Läkemedelsfond
The board of SEB Funds AB decided on 8 September 2025 to merge SEB Concept Biotechnology into the Sweden-domiciled healthcare fund SEB Läkemedelsfond. The two funds have similar investment objectives, strategies and risk profiles, although the receiving fund has a higher minimum allocation to sustainable investments of 20%, compared with 10% for SEB Concept Biotechnology.
Investors are not required to take any action and will receive units in SEB Läkemedelsfond equal in value to their existing holdings. The merger is intended to simplify SEB’s fund range and improve management efficiency and cost-effectiveness.
Share this article